Romanchuk Anastasiia, Bravi Michela, Tebaldi Paola, D'Antiga Lorenzo, Norsa Lorenzo
Pediatric Hepatology, Gastroenterology and Transplantation, ASST Papa Giovanni XXIII Bergamo Italy.
Department of Pediatrics, Pediatric Infectious Diseases, Immunology and Allergology Shupyk National Medical University of Ukraine Kyiv Ukraine.
JPGN Rep. 2024 May 27;5(3):407-410. doi: 10.1002/jpr3.12082. eCollection 2024 Aug.
Teduglutide is a glucagon-like peptide 2 (GLP-2) analog which acts by increasing intestinal absorption of the remnant bowel for children with short bowel syndrome (SBS) dependent on parenteral nutrition. We present a 13-year-old male patient with type 2 SBS (55 cm of jejunum) from necrotizing enterocolitis on full oral feeding from the age of 12 months. Because of faltering growth from the age of 11 despite oral hyperphagia, he started Teduglutide at the standard dose. Eighteen months after Teduglutide start the young boy gained 10 kg in weight and 13 cm in height with a significant reduction in bowel distension. No adverse events were reported during the treatment. Pubertal spurt might be impaired in children with SBS on full oral feeding if the caloric need is not met by the residual intestinal absorption rate. GLP-2 analog might represent an option to sustain pubertal spurt in SBS children on full oral feeding with hyperphagia.
替度鲁肽是一种胰高血糖素样肽2(GLP - 2)类似物,其作用机制是增加短肠综合征(SBS)患儿残余肠道的肠吸收,这些患儿依赖肠外营养。我们报告一名13岁男性2型SBS患者(空肠55厘米),因坏死性小肠结肠炎导致,自12个月大起完全经口喂养。尽管自11岁起食欲亢进但生长发育迟缓,他开始使用标准剂量的替度鲁肽。开始使用替度鲁肽18个月后,这个小男孩体重增加了10千克,身高增加了13厘米,肠扩张明显减轻。治疗期间未报告不良事件。如果残余肠吸收率不能满足热量需求,完全经口喂养的SBS患儿的青春期发育突增可能会受到影响。GLP - 2类似物可能是维持完全经口喂养且食欲亢进的SBS患儿青春期发育突增的一种选择。